The atlas at a glance
A data view of where the 36 current entries sit — by evidence standing, by portal, and across the risk-versus-reversibility space that decides how much proof a claim should carry.
Entries
36
across 8 portals
Avg. evidence
2.8
on a 1–4 scale
High risk
11
12 hard to reverse
Reviewed
6
27 glossary terms
Evidence by portal
Show as table
| Portal | Speculative | Preclinical | Early human | Clinical practice | Total |
|---|---|---|---|---|---|
| Longevity Science | 0 | 2 | 4 | 0 | 6 |
| Genetic Modification | 1 | 0 | 1 | 2 | 4 |
| Frontier Biotech | 0 | 1 | 3 | 0 | 4 |
| Future Pharma | 0 | 1 | 2 | 2 | 5 |
| Cybernetics | 0 | 0 | 2 | 2 | 4 |
| Biohacking & Risk | 2 | 0 | 0 | 1 | 3 |
| Reproduction & Development | 0 | 3 | 2 | 0 | 5 |
| Mind & Cognition | 1 | 1 | 2 | 1 | 5 |
Risk vs. reversibility
The upper-right corner — high risk and hard to reverse — is where a claim should carry the most proof. Darker cells hold more entries.
Risk →
H2
H3
H3
H3
M7
M1
M4
M1
M3
L4
U3
U2
ReversiblePartlyContextDifficultIrrevers.
Reversibility →
Rows top→bottom: High · Moderate · Low · Unknown risk
Overall evidence mix
Speculative4
Preclinical8
Early human16
Clinical practice8
Dig in
16 milestones sit on the timeline. Put entries head to head in the compare view, or browse the full filtered index.